Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acetylcysteine/enoxaparin - Atossa Therapeutics

Next Previous
X
Search
Drug Profile

Acetylcysteine/enoxaparin - Atossa Therapeutics

Alternative Names: AT-H201; Enoxaparin/acetylcysteine - Atossa Therapeutics; Enoxaparin/N-Acetylcysteine - Atossa Therapeutics; N-Acetylcysteine/enoxaparin - Atossa Therapeutics

Latest Information Update: 23 Mar 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Atossa Therapeutics
  • Class Anti-inflammatories; Anti-ischaemics; Antibronchitics; Antidotes; COVID-19 vaccines; Expectorants; Ischaemic heart disorder therapies; Low molecular weight heparins; Reducing agents; Small molecules; Sulfur amino acids
  • Mechanism of Action Antioxidants; Factor Xa inhibitors; Free radical inhibitors; Glutamate receptor modulators; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II COVID 2019 infections

Most Recent Events

  • 23 Mar 2023 Atossa Therapeutics plans a clinical trial in patients with compromised lung-function due to the damaging effects of cancer treatment (Atossa Therapeutics pipeline, March 2023)
  • 30 Sep 2021 Phase-I/II clinical trials in COVID-2019 infections in Australia (Inhalation)
  • 02 Sep 2021 Atossa Therapeutics plans a phase I/IIa trial for COVID-2019 infections in Australia and USA (ACTRN12621000704897p)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top